Revimmune cyclophosphamide regulatory update

FDA granted Orphan Drug designation for Accentia's Revimmune cyclophosphamide to treat systemic sclerosis and autoimmune hemolytic anemia. The ultra-high intensity, short-course of an IV formulation of cyclophosphamide is slated to begin Phase III testing to treat multiple sclerosis (MS) in early 2012. ...